Based on results from a phase 3 clinical trial, TAP Pharmaceutical Products Inc., the makers of febuxostat, have submitted an application seeking FDA approval for febuxostat in the management of hyperuricemia in patients with chronic gout. Results from a Phase 3 clinical trial showed that daily oral febuxostat (80 or 120 mg) is effective in reducing the level of serum uric acid in subjects with gout and hyperuricemia compared to allopurinol 300 mg per day. Safety of both doses of febuxostat was comparable to allopurinol, currently the only approved treatment for gout.
Receive the Latest News from Johns Hopkins Rheumatology
Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.
